Pharmacy
CMS intends to send the first invoices in 2025 to manufacturers for the rebates owed to Medicare in 2023 and 2024.
The move is an effort to expand and accelerate pharmacy care delivery for patients with chronic and complex care needs.
Two organizations protest that treatment is no more accessible than under the agency's current clinical trial policy.
The initiatives are meant to connect patients to services addressing needs such as food transportation, housing and baby supplies.
HIMSS23
<p>DrFirst's AI-driven medication algorithm can read the intent of the prescription renewal request, says CMO Dr. Colin Banas.</p>
<p> </p>
A provision in the IRA would ameliorate the out-of-pocket spending increases when people transition from commercial insurance to Part D.
The rule would allow CMS to have more insight into what the most expensive drugs on the market actually cost to manufacture and distribute.
Contracts with managed care plans would include a report on spread pricing, CMS says.
Patient demand could result in expanded coverage, but it could cost the federal program between $13.6 and $26.8 billion annually.
The House Committee on Oversight and Accountability will take up the role of pharmacy benefit managers on Tuesday, May 23.